

Resource Summary Report

Generated by PRECISE-TBI on Aug 9, 2026

PI 3-kinase p110alpha (H-201)

RRID:AB_2252476

Type: Antibody

Proper Citation

Santa Cruz Biotechnology Cat# sc-7174, RRID:AB_2252476

Antibody Information

URL: http://antibodyregistry.org/AB_2252476

Proper Citation: Santa Cruz Biotechnology Cat# sc-7174, RRID:AB_2252476

Target Antigen: ND

Host Organism: rabbit

Clonality: unknown

Comments: Discontinued: 2016; Used By NYUIHC-382

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: PI 3-kinase p110alpha (H-201)

Description: This unknown targets ND

Target Organism: mouse, human

Antibody ID: AB_2252476

Vendor: Santa Cruz Biotechnology

Catalog Number: sc-7174

Record Creation Time: 20250819T230924+0000

Record Last Update: 20250820T042751+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

Warning: Discontinued: 2016

Discontinued: 2016; Used By NYUIHC-382

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Oh S, et al. (2023) Non-bioenergetic roles of mitochondrial GPD2 promote tumor progression. Theranostics, 13(2), 438.